Regorafenib plus programmed death‑1 inhibitors vs. regorafenib monotherapy in second‑line treatment for advanced hepatocellular carcinoma: A systematic review and meta‑analysis.

Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: eCollection Cited Medium: Internet ISSN: 1792-1082 (Electronic) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE

Original Publication: [Athens : Spandidos Publications]

The present study compared the efficacy and safety of regorafenib plus programmed death-1 inhibitors (R-P) with regorafenib monotherapy as second-line therapies for advanced hepatocellular carcinoma (HCC). A systematic search of relevant literature published in PubMed, Embase, Web of Science and Cochrane Library databases until October 2023 was conducted. Two authors independently performed data extraction and screening using standardized protocols. Stata/MP 17.0 was used for the meta-analysis to evaluate the impact of R-P treatment on major outcome indicators, including overall survival, progression-free survival (PFS), tumor response and adverse reactions, in patients with advanced HCC. The results indicated that five cohort studies involving 444 patients with advanced HCC were included. The results revealed that R-P treatment improved overall survival [hazard ratio (HR), 0.61; 95% confidence interval (CI) 0.48-0.77; I ² =0.0%; P=0.663] and PFS (HR, 0.51; 95% CI 0.41-0.63; I ² =17.5%; P=0.303). Additionally, it increased the objective response rate (risk ratio, 2.33; 95% CI, 1.49-3.64; I ² =0.0%; P=0.994) and disease control rate (HR, 1.40; 95% CI, 1.20-1.63; I ² =0.0%; P=0.892) compared with those of regorafenib. However, R-P treatment was associated with an increased incidence of adverse events, such as hypothyroidism, thrombocytopenia and rash, compared with that in regorafenib. In conclusion, R-P is superior to regorafenib monotherapy in terms of survival benefits and tumor response.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © 2024 Li et al.)

Lancet Oncol. 2018 Jul;19(7):940-952. (PMID: 29875066)
Lancet. 2018 Mar 24;391(10126):1163-1173. (PMID: 29433850)
Int J Cancer. 2011 Jul 1;129(1):245-55. (PMID: 21170960)
Ann Transl Med. 2023 Jan 31;11(2):109. (PMID: 36819518)
Lancet. 2022 Oct 15;400(10360):1345-1362. (PMID: 36084663)
Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959. (PMID: 34104211)
Clin Exp Med. 2022 Feb;22(1):65-74. (PMID: 34146196)
Dig Dis. 2016;34(6):714-730. (PMID: 27750243)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. (PMID: 36369487)
Drugs. 2018 Jun;78(9):951-958. (PMID: 29915898)
Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514)
J Hepatocell Carcinoma. 2022 Mar 10;9:157-170. (PMID: 35300208)
Biomed Pharmacother. 2023 Mar;159:114254. (PMID: 36669362)
Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. (PMID: 36794716)
J Clin Oncol. 2020 Jan 20;38(3):193-202. (PMID: 31790344)
Onco Targets Ther. 2022 Oct 01;15:1079-1094. (PMID: 36212725)
J Gastrointest Oncol. 2023 Dec 31;14(6):2549-2558. (PMID: 38196523)
J Gastrointest Oncol. 2021 Dec;12(6):2943-2951. (PMID: 35070420)
Int Immunopharmacol. 2022 Dec;113(Pt B):109401. (PMID: 36395672)
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. (PMID: 38059174)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33234602)
Lancet Oncol. 2021 Jul;22(7):991-1001. (PMID: 34051880)
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. (PMID: 34764464)
Lancet. 2017 Jan 7;389(10064):56-66. (PMID: 27932229)
J Hepatocell Carcinoma. 2023 Jun 20;10:949-958. (PMID: 37361905)
Clin Cancer Res. 2019 Jul 15;25(14):4530-4541. (PMID: 30940655)
Nat Med. 2024 Mar;30(3):699-707. (PMID: 38374347)
Invest New Drugs. 2019 Jun;37(3):567-572. (PMID: 30523474)
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224)
Ther Clin Risk Manag. 2023 Apr 05;19:329-339. (PMID: 37041973)
Curr Treat Options Oncol. 2023 Jul;24(7):711-724. (PMID: 37103744)
Cancer Treat Rev. 2020 Jun;86:101993. (PMID: 32199197)
Oncology. 2021;99(8):491-498. (PMID: 34000725)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)

Keywords: hepatocellular carcinoma; meta-analysis; programmed death-1; regorafenib

Date Created: 20240529 Latest Revision: 20240530

20250114

PMC11130614

10.3892/ol.2024.14451

38807680